Research suggests biosimilar medications may offer comparable treatment at lower costs, potentially improving access for people with albinism who develop psoriasis.
For people with albinism who develop psoriasis, access to effective biologics treatments can be life-changing — but often cost-prohibitive. New research published in the Journal of Investigative Dermatology offers hope that more affordable alternatives could expand treatment access worldwide.
Researchers reviewing biosimilar medications for moderate-to-severe psoriasis treatment found they demonstrated comparable efficacy and safety to their original biologic counterparts, according to the study. These biosimilars — essentially generic versions of complex biologic drugs — could significantly improve cost-effectiveness of treatment.
Global access challenges
The research specifically examined how biosimilars might improve access to biologics for psoriasis treatment in low-and-middle-income countries, where many people with albinism reside and where treatment costs often limit access to original biologics.
The analysis was conducted as part of a systematic review supporting the submission process to include adalimumab and ustekinumab in the World Health Organization's Essential Medicines List for psoriasis.
This development is particularly relevant for the albinism community as individuals with albinism face heightened susceptibility to various skin conditions, including psoriasis, due to their reduced melanin protection. Access to affordable, effective treatments could substantially improve quality of life.
As healthcare systems worldwide grapple with rising costs, these findings suggest biosimilars could be a promising pathway to expand treatment access for people with albinism who require advanced psoriasis care, especially in regions where healthcare resources are limited.
Keywords
Core topics and entities mentioned in this summary.